Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
20 mars 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, March 20, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), an immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Therapeutics Reports Annual 2017 Financial and Operating Results
09 mars 2018 07h00 HE
|
Trillium Therapeutics Inc.
Presented evidence of clinical activity and good tolerability from both TTI-621 trials at ASHReceived FDA clearance to proceed with second clinical CD47 program, TTI-622Cash and marketable securities...
Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621
17 janv. 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Therapeutics Provides Update on its TTI-621 Program at the American Society of Hematology 59th Annual Meeting
11 déc. 2017 08h00 HE
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Dec. 11, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Announces Closing of Private Placement
01 déc. 2017 22h21 HE
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Dec. 1, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Therapeutics' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting
20 nov. 2017 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Nov. 20, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Announces Private Placement
15 nov. 2017 09h15 HE
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Nov. 15, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Therapeutics' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting
13 nov. 2017 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Nov. 13, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results
10 nov. 2017 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Nov. 10, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the...
Trillium Therapeutics to Present at Upcoming Scientific Conferences
06 nov. 2017 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, ONTARIO--(Marketwired - Nov. 6, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the...